CN116133669A - 用于抑制包括冠状病毒感染的病毒感染的材料和方法 - Google Patents

用于抑制包括冠状病毒感染的病毒感染的材料和方法 Download PDF

Info

Publication number
CN116133669A
CN116133669A CN202180059965.6A CN202180059965A CN116133669A CN 116133669 A CN116133669 A CN 116133669A CN 202180059965 A CN202180059965 A CN 202180059965A CN 116133669 A CN116133669 A CN 116133669A
Authority
CN
China
Prior art keywords
biofilm
seq
virus
protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059965.6A
Other languages
English (en)
Chinese (zh)
Inventor
尼古拉斯·T·蒙苏尔
埃瓦·A·贝尔克斯
弗雷德里克·T·勃姆
廖育贤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quorum Innovations Inc
Original Assignee
Quorum Innovations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quorum Innovations Inc filed Critical Quorum Innovations Inc
Publication of CN116133669A publication Critical patent/CN116133669A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180059965.6A 2020-06-06 2021-06-07 用于抑制包括冠状病毒感染的病毒感染的材料和方法 Pending CN116133669A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035733P 2020-06-06 2020-06-06
US63/035,733 2020-06-06
PCT/US2021/036104 WO2021248111A1 (en) 2020-06-06 2021-06-07 Materials and methods for inhibiting a viral infection, including a coronavirus infection

Publications (1)

Publication Number Publication Date
CN116133669A true CN116133669A (zh) 2023-05-16

Family

ID=78831585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059965.6A Pending CN116133669A (zh) 2020-06-06 2021-06-07 用于抑制包括冠状病毒感染的病毒感染的材料和方法

Country Status (11)

Country Link
US (2) US11826390B2 (https=)
EP (1) EP4161558A4 (https=)
JP (1) JP2023529152A (https=)
KR (1) KR20230025853A (https=)
CN (1) CN116133669A (https=)
AU (1) AU2021286002A1 (https=)
BR (1) BR112022024911A2 (https=)
CA (1) CA3180737A1 (https=)
IL (1) IL298401A (https=)
MX (1) MX2022015439A (https=)
WO (1) WO2021248111A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006163A (es) * 2019-11-26 2022-06-17 Quorum Innovations Llc Nuevas composiciones de barrera protectora y usos de las mismas.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1701116A (zh) * 2002-09-06 2005-11-23 Vri生物医学有限公司 益生细菌:发酵乳杆菌
WO2007040445A1 (en) * 2005-10-06 2007-04-12 Probi Ab Use of lactobacillus for treatment of virus infections
WO2010027344A1 (en) * 2008-09-04 2010-03-11 Om Pharma Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
WO2012141540A2 (ko) * 2011-04-13 2012-10-18 씨제이제일제당 (주) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
CN108135947A (zh) * 2015-07-20 2018-06-08 群体创新有限责任公司 提高免疫应答和皮肤和/或粘膜屏障功能的材料和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3176797A1 (en) * 2020-05-06 2021-11-11 Nicholas T. Monsul Novel protein, and therapeutic and cosmetic uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1701116A (zh) * 2002-09-06 2005-11-23 Vri生物医学有限公司 益生细菌:发酵乳杆菌
WO2007040445A1 (en) * 2005-10-06 2007-04-12 Probi Ab Use of lactobacillus for treatment of virus infections
WO2010027344A1 (en) * 2008-09-04 2010-03-11 Om Pharma Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
WO2012141540A2 (ko) * 2011-04-13 2012-10-18 씨제이제일제당 (주) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
CN108135947A (zh) * 2015-07-20 2018-06-08 群体创新有限责任公司 提高免疫应答和皮肤和/或粘膜屏障功能的材料和方法

Also Published As

Publication number Publication date
US20230136276A1 (en) 2023-05-04
AU2021286002A1 (en) 2023-01-19
JP2023529152A (ja) 2023-07-07
EP4161558A1 (en) 2023-04-12
BR112022024911A2 (pt) 2022-12-27
US20240075083A1 (en) 2024-03-07
KR20230025853A (ko) 2023-02-23
WO2021248111A1 (en) 2021-12-09
EP4161558A4 (en) 2024-06-19
IL298401A (en) 2023-01-01
MX2022015439A (es) 2023-03-22
CA3180737A1 (en) 2021-12-09
WO2021248111A9 (en) 2022-12-22
US11826390B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
EP3274472B1 (en) Antimicrobial peptides and methods of use thereof
KR20130043625A (ko) 화합물들 및 그 용도
CN111617108A (zh) 眼镜蛇科蛇突触后神经毒素、心脏毒素、细胞毒素、磷脂酶a2及粗毒在抗病毒感染上的应用
US12495800B2 (en) Protective barrier compositions, and uses thereof
KR20180037185A (ko) 광범위의 항감염성 펩티드
KR20170072291A (ko) 치료 방법
CN112717122A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
US20250295748A1 (en) Treatment and prevention of viral infections
US20240075083A1 (en) Materials and methods for inhibiting a viral infection, including a coronavirus infection
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
CN111346212A (zh) 活性多肽在制备抗冠状病毒药物及医用食品中的应用
DK2370088T3 (en) Nanopeptides derived from mammalian colostrum for broad-spectrum viral and recurrent infections and methods for isolation thereof
CN102516394A (zh) CMG2突变体和Fc的融合蛋白及其编码基因与应用
KR101443233B1 (ko) 황색포도상구균 감염 치료용 의약을 제조하기 위한 활성 성분으로서의 ｔｒａｐ 자체의 용도
KR20200033828A (ko) 세포투과성 펩타이드와 ctCTLA4 펩타이드가 융합된 융합단백질을 유효성분으로 하는 염증성 호흡기 질환 예방 또는 치료용 약학 조성물
WO2024079492A1 (en) Corynebacterium strains, combinations, and lyophilized formulations thereof for use in the prevention of a viral infection
KR101754756B1 (ko) 재조합 백시니아바이러스를 이용한 탄저/두창 2가 백신후보주
WO2024102995A1 (en) Compositions and methods for treating and preventing human chlamydial infections and diseases using attenuated animal chlamydia
WO2024125810A1 (en) Formulations for nasal covid-19 vaccines
KR20160000949A (ko) Rankl를 생산하는 재조합 유산균 및 이의 용도
KR20220007963A (ko) 신규한 세포 내 단백질 전달 방법
WO2022104073A1 (en) Defensins as inhibitors of sars-cov-2 infection and uses thereof
CN109575107A (zh) 一种细胞穿透肽及可表达口服干扰素的双歧杆菌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230516